Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms

13 Aug 2020

Abstract excerpt

Myeloproliferative neoplasms are divided into essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Although ruxolitinib was proven to be effective in reducing symptoms, patients rarely achieve complete molecular remission. Therefore, it is relevant to identify new therapeutic targets to improve the clinical outcome of patients. Bcl-xL protein, the long isoform encoded by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32790151
DOI: 10.1111/jcmm.15730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasmsPMID 32790151Read ↗

Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.Semantic proximity Read ↗

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.Semantic proximity Read ↗

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.Semantic proximity Read ↗

The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETOSemantic proximity Read ↗

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cellsSemantic proximity Read ↗

Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.Semantic proximity Read ↗

The Role of Bcl-xL Protein in Viral InfectionsSemantic proximity Read ↗

Alternative splicing of BCL‑X and implications for treating hematological malignancies (Review)Semantic proximity Read ↗

Expression of Bcl-x in Erythroid Precursors from Patients with Polycythemia VeraSemantic proximity Read ↗

Expression and prognostic significance of Bcl‐2 family proteins in myelodysplastic syndromesSemantic proximity Read ↗

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity Read ↗

Gene expression profiling of normal and malignant CD34-derived megakaryocytic cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.